Fuyuan Pharmaceutical announced that the company participated in the 12th batch of centralized procurement of national drugs. The products saxagliptin metformin extended-release tablets and megasartan potassium tablets will be selected. The procurement period is until December 31, 2029. The domestic market sales amount of saxagliptin metformin extended-release tablets in 2025 was about 50594 million yuan, and measartan potassium tablets were about 11.9657 million yuan. Products such as dapagliflozin metformin extended-release tablets did not win the bid.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.